U.S. Government and Big Tech Companies Invest 2.4 Trillion Won in AI Bio Sector

2026-10-11

Recently, the U.S. government and major big tech companies decided to make a large-scale investment of approximately 2.4 trillion won in the bio industry utilizing artificial intelligence (AI). This collaboration aims to shorten the drug development period and increase the efficiency of disease treatment through AI technology.

As AI technology integrates with the bio sector, significant changes are occurring in the drug development process. Previously, it took years to develop a new drug, but by utilizing AI, vast amounts of data can be analyzed rapidly to identify candidate substances. These technological advancements are becoming key factors in enhancing the competitiveness of the global pharmaceutical industry.

South Korea is also accelerating AI-based drug development in line with this global trend. Domestic pharmaceutical and bio companies are striving to increase the success rate of drug development and reduce costs by adopting AI technology. The government is also supporting related technology research and talent cultivation to secure competitiveness in the global market.

This collaboration between the U.S. government and big tech companies is expected to change the standards of the global bio industry in the future. Much attention is focused on what kind of achievements Korean companies can attain amidst these changes.